FDA clears phase 3 Ph+ ALL trial in US and EU
What happened
The FDA and EMA both cleared a phase 3 trial testing olverembatinib with low‑intensity chemotherapy in newly diagnosed Philadelphia‑positive acute lymphoblastic leukemia, reflecting coordinated regulator alignment. Early data from the program showed about 65% MRD‑negativity, and the parallel clearances suggest growing harmonization around molecular endpoints like MRD. That joint approach can simplify global safety reporting standards and encourage unified post‑market surveillance plans across regions. (cancernetwork.com)
Why it matters
The US Food and Drug Administration and the European Medicines Agency both cleared a single, global late‑stage clinical trial testing a new oral cancer drug combined with lower‑intensity chemotherapy in people who have just been diagnosed with a specific, aggressive form of acute lymphoblastic leukemia caused by a chromosomal abnormality; the study is sponsored by Ascentage Pharma and is registered as POLARIS‑1 (NCT06051409). (ascentage.com) (cancernetwork.com) Both agencies cleared the same protocol so Ascentage can enroll patients across regions under one registrational study instead of running separate regional trials, which the company says is intended to accelerate the drug’s path to approval in the US and Europe. (ascentage.com) (cancernetwork.com) The investigational drug, olverembatinib (HQP1351), is described by the sponsor as an oral, third‑generation tyrosine kinase inhibitor — a class of small molecules that block a signaling enzyme inside cancer cells that drives their growth; olverembatinib specifically targets the abnormal fusion enzyme produced by the chromosomal swap that defines this leukemia subtype. (cancernetwork.com) (ascentage.com) POLARIS‑1 is a global, randomized, open‑label Phase 3 trial that assigns patients to olverembatinib plus low‑intensity chemotherapy or to imatinib (a first‑generation oral kinase inhibitor) plus chemotherapy, with an estimated enrollment of approximately 350 patients and an estimated primary completion date in late 2028; the sponsor presented an initial dataset at the 2025 American Society of Hematology meeting. (clinicaltrials.gov) (cancernetwork.com) (targetedonc.com) Early POLARIS‑1 data released by Ascentage showed that after three induction cycles roughly two‑thirds of patients were negative for minimal residual disease — a laboratory measure that detects very small numbers of remaining cancer cells and that correlates with lower relapse risk — and that molecular complete response rates were in the mid‑60% range; the sponsor also reported deep molecular responses in a high‑risk subgroup defined by IKZF1plus alterations. (ascentage.com) (cancernetwork.com) Operational and regulatory context: olverembatinib already has regulatory approvals in China for certain chronic myeloid leukemia indications and is the subject of an option agreement with Takeda for ex‑China rights, which means an existing safety and commercial footprint will feed into global pharmacovigilance planning; when a single registrational protocol is cleared across major authorities, sponsors typically map expedited‑reporting workflows to ICH E2A definitions (timelines for suspected unexpected serious adverse reaction reporting) and to EU mechanisms such as EudraVigilance under the EU Clinical Trials Regulation. (takeda.com) (ascentage.com) (database.ich.org) (ema.europa.eu)
Key numbers
- The FDA and EMA both cleared a phase 3 trial testing olverembatinib with low‑intensity chemotherapy in newly diagnosed Philadelphia‑positive acute lymphoblastic leukemia, reflecting coordinated regulator alignment.
- Early data from the program showed about 65% MRD‑negativity, and the parallel clearances suggest growing harmonization around molecular endpoints like MRD.
What happens next
- That joint approach can simplify global safety reporting standards and encourage unified post‑market surveillance plans across regions.
Quick answers
What happened in FDA clears phase 3 Ph+ ALL trial in US and EU?
The FDA and EMA both cleared a phase 3 trial testing olverembatinib with low‑intensity chemotherapy in newly diagnosed Philadelphia‑positive acute lymphoblastic leukemia, reflecting coordinated regulator alignment. Early data from the program showed about 65% MRD‑negativity, and the parallel clearances suggest growing harmonization around molecular endpoints like MRD. That joint approach can simplify global safety reporting standards and encourage unified post‑market surveillance plans across regions. (cancernetwork.com)
Why does FDA clears phase 3 Ph+ ALL trial in US and EU matter?
The US Food and Drug Administration and the European Medicines Agency both cleared a single, global late‑stage clinical trial testing a new oral cancer drug combined with lower‑intensity chemotherapy in people who have just been diagnosed with a specific, aggressive form of acute lymphoblastic leukemia caused by a chromosomal abnormality; the study is sponsored by Ascentage Pharma and is registered as POLARIS‑1 (NCT06051409). (ascentage.com) (cancernetwork.com) Both agencies cleared the same protocol so Ascentage can enroll patients across regions under one registrational study instead of running separate regional trials, which the company says is intended to accelerate the drug’s path to approval in the US and Europe. (ascentage.com) (cancernetwork.com) The investigational drug, olverembatinib (HQP1351), is described by the sponsor as an oral, third‑generation tyrosine kinase inhibitor — a class of small molecules that block a signaling enzyme inside cancer cells that drives their growth; olverembatinib specifically targets the abnormal fusion enzyme produced by the chromosomal swap that defines this leukemia subtype. (cancernetwork.com) (ascentage.com) POLARIS‑1 is a global, randomized, open‑label Phase 3 trial that assigns patients to olverembatinib plus low‑intensity chemotherapy or to imatinib (a first‑generation oral kinase inhibitor) plus chemotherapy, with an estimated enrollment of approximately 350 patients and an estimated primary completion date in late 2028; the sponsor presented an initial dataset at the 2025 American Society of Hematology meeting. (clinicaltrials.gov) (cancernetwork.com) (targetedonc.com) Early POLARIS‑1 data released by Ascentage showed that after three induction cycles roughly two‑thirds of patients were negative for minimal residual disease — a laboratory measure that detects very small numbers of remaining cancer cells and that correlates with lower relapse risk — and that molecular complete response rates were in the mid‑60% range; the sponsor also reported deep molecular responses in a high‑risk subgroup defined by IKZF1plus alterations. (ascentage.com) (cancernetwork.com) Operational and regulatory context: olverembatinib already has regulatory approvals in China for certain chronic myeloid leukemia indications and is the subject of an option agreement with Takeda for ex‑China rights, which means an existing safety and commercial footprint will feed into global pharmacovigilance planning; when a single registrational protocol is cleared across major authorities, sponsors typically map expedited‑reporting workflows to ICH E2A definitions (timelines for suspected unexpected serious adverse reaction reporting) and to EU mechanisms such as EudraVigilance under the EU Clinical Trials Regulation. (takeda.com) (ascentage.com) (database.ich.org) (ema.europa.eu)
